Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Anita Ramelius

Biomedical analyst

Default user image.

Antibodies to influenza virus A/H1N1 hemagglutinin in type 1 diabetes children diagnosed before, during and after the Swedish A(H1N1)pdm09 vaccination campaign 2009-2010.

Author

  • Matilda1 Svensson
  • Anita Ramelius
  • Anna-Lena Nilsson
  • Ahmed Delli
  • Helena Larsson
  • Annelie Carlsson
  • Gun Forsander
  • Sten Ivarsson
  • Johnny Ludvigsson
  • Ingrid Kockum
  • Claude Marcus
  • Ulf Samuelsson
  • Eva Ortqvist
  • Åke Lernmark

Summary, in English

We determined A/H1N1-HA antibodies in relation to HLA-DQ genotypes and islet autoantibodies at clinical diagnosis in 1141 incident 0.7-18 years old type 1 diabetes patients diagnosed April 2009 - December 2010. Antibodies to (35) S-methionine-labeled A/H1N1 hemagglutinin were determined in a radiobinding assay in patients diagnosed before (n=325), during (n=355) and after (n=461) the October 2009 - March 2010 Swedish A(H1N1)pdm09 vaccination campaign, along with HLA-DQ genotypes and autoantibodies against GAD, insulin, IA-2 and ZnT8 transporter. Before vaccination, 0.6% patients had A/H1N1-HA antibodies compared to 40% during and 27% after vaccination (p<0.0001). In children <3 years of age, A/H1N1-HA antibodies were found only during vaccination. The frequency of A/H1N1-HA antibodies during vaccination decreased after vaccination among the 3<6 (p=0.006) and 13<18 (p=0.001) but not among the 6<13 year olds. HLA-DQ2/8 positive children <3 years decreased from 54% (15/28) before and 68% (19/28) during, to 30% (9/30) after vaccination (p=0.014). Regardless of age, DQ2/2; 2/X (n=177) patients had lower frequency (p=0.020) and levels (p=0.042) of A/H1N1-HA antibodies compared to non-DQ2/2; 2/X (n=964) patients. GADA frequency was 50% before, 60% during and 51% after vaccination (p=0.009). ZnT8QA frequency increased from 30% before to 34% during and 41% after vaccination (p=0.002). Our findings suggest that young (<3 years) along with DQ2/2; 2/X patients were low responders to Pandemrix(®) . As the proportion of DQ2/8 patients <3 years of age decreased after vaccination and the frequencies of GADA and ZnT8QA were enhanced, it cannot be excluded that the vaccine affected clinical onset of type 1 diabetes. This article is protected by copyright. All rights reserved.

Department/s

  • Diabetes and Celiac Unit
  • Paediatric Endocrinology
  • Paediatrics (Lund)
  • EXODIAB: Excellence of Diabetes Research in Sweden

Publishing year

2014

Language

English

Pages

137-148

Publication/Series

Scandinavian Journal of Immunology

Volume

79

Issue

2

Document type

Journal article

Publisher

Wiley-Blackwell

Topic

  • Immunology in the medical area

Status

Published

Research group

  • Diabetes and Celiac Unit
  • Paediatric Endocrinology

ISBN/ISSN/Other

  • ISSN: 1365-3083